MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-05-2025
BioMarin Pharmaceutical DPO Ratio 2011-2025 | BMRN
Annual DPO Ratio BioMarin Pharmaceutical
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 245 | 240 | 252 | 333 | 431 | 369 | 363 | 267 | 53.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 431 | 53.2 | 284 |
Quarterly DPO Ratio BioMarin Pharmaceutical
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.2 | 59.6 | 83 | - | 90.6 | 79.7 | 139 | - | 120 | 149 | 136 | - | 88.9 | 92.9 | 96.6 | - | 49.8 | 58 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 149 | 34.2 | 91.2 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.79 | 2.35 % | $ 795 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
887 | $ 3.04 | 4.83 % | $ 235 M |  USA |
 |
Aptorum Group Limited
APM
|
405 | $ 1.17 | 4.46 % | $ 6.38 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptevo Therapeutics
APVO
|
239 | $ 0.93 | -8.81 % | $ 257 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
28.5 | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
54.4 | $ 9.48 | 0.96 % | $ 139 M | USA |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
Axon Enterprise
AXON
|
29.9 | $ 591.15 | 0.02 % | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
186 | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
265 | $ 92.45 | 0.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | USA |
 |
Catalyst Biosciences
CBIO
|
18.8 | $ 12.37 | 2.06 % | $ 814 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
199 | $ 10.81 | 2.95 % | $ 699 M | USA |
 |
Biogen
BIIB
|
65.4 | $ 176.33 | 0.86 % | $ 25.7 B | USA |
 |
Abeona Therapeutics
ABEO
|
2.52 K | $ 5.41 | 2.08 % | $ 116 M | USA |
 |
ADiTx Therapeutics
ADTX
|
5.15 K | $ 1.14 | -9.52 % | $ 15 K | USA |